Insider transactions

MICHAEL W ROGERS

CIK 1244159 · See Remarks · last filed 2026-06-22

MICHAEL W ROGERS is a corporate insider who has filed 56 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for AKBA, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$405.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $209.5K across reported positions. 3 SEC filings were submitted jointly with Fortress Biotech, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$209.5K

Companies

10

Total Filings

56

Lifetime Open-Market Net

-$405.9K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O AKEBIA THERAPEUTICS, INC
245 FIRST STREET
CAMBRIDGE, MA 02142
Related Filers
Fortress Biotech, Inc. — 3 joint filings, latest 2013-02-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AKBA Director 197,429 $0.86 $170.8K $0 9 2026-06-22
Aravive, Inc. (ARAV) Delisted Director — $0.04 — $0 3 2022-09-26
EYPT Director 11,917 $3.25 $38.7K $0 5 2019-06-27
Whitehawk Therapeutics, Inc. (ARPO) Delisted See Remarks — $33.00 — $0 2 2019-05-16
KERYX BIOPHARMACEUTICALS INC (KERX) Delisted Director 0 — — $0 4 2018-12-13
EyePoint, Inc. (PSDV) Delisted Director — — — $0 11 2017-12-19
Acorda Therapeutics, Inc. (ACOR) Delisted Chief Financial Officer 339 $0.66 $224 -$405.9K 10 2016-05-13
Fortress Biotech, Inc. (CNDO) Delisted Director — — — $0 2 2013-02-11
BG Medicine, Inc. (BGMD) Delisted EVP, CFO and Treasurer — — — $0 2 2012-02-24
IDEV Executive Vice President 0 $89.58 $0 $0 6 2009-02-25

Recent Filings

56 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 AKBA Grant (A) +35,700 $0 EDGAR
2025-06-11 AKBA Grant (A) +35,700 $0 EDGAR
2024-06-10 AKBA Grant (A) +30,000 $0 EDGAR
2023-06-08 AKBA Grant (A) +30,000 $0 EDGAR
2022-09-26 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2022-06-09 AKBA Grant (A) +13,700 $0 EDGAR
2021-09-13 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2021-06-03 AKBA Grant (A) +13,700 $0 EDGAR
2020-09-17 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2020-06-09 AKBA Grant (A) +13,700 $0 EDGAR
Showing 1–10 of 56
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.